Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells

Area of Science:

• Immunology
• Virology
• Molecular Biology

Background:

• Viral mutations can lead to T cell receptor (TCR) antagonistic activity, correlating with infection severity.
• Hepatitis C virus (HCV) persistence is linked to antigen modifications, with TCR antagonism previously shown in CD8+ T cells.
• CD4+ T cell antagonism by HCV may represent a mechanism for immune evasion, as effective T helper cell responses are associated with self-limited infections.

Purpose of the Study:

• To investigate whether Hepatitis C virus (HCV) variants, specifically in the hypervariable region 1 (HVR1), can act as T cell receptor (TCR) antagonists for CD4+ T cells.
• To provide the first evidence of TCR antagonism mediated by naturally occurring HCV class II-restricted T cell epitopes.

Main Methods:

• Utilized classical antagonism assays to assess the impact of HVR1 variants on CD4+ T cell responses.
• Isolated HVR1-specific CD4+ T cells from individuals infected with HCV.
• Analyzed inhibition of cellular proliferation and cytokine production upon simultaneous presentation of agonist and antagonist ligands by antigen-presenting cells (APCs).

Main Results:

• Demonstrated that HVR1 variants of HCV function as potent TCR antagonists for HVR1-specific CD4+ T cells from infected individuals.
• Observed significant inhibition of T cell proliferation and cytokine production when agonist and antagonist ligands were co-presented by APCs.
• Identified conserved residues within HVR1 critical for HLA-DR binding, supporting their role as TCR antagonists.

Conclusions:

• Naturally occurring HCV HVR1 variants can induce TCR antagonism in CD4+ T cells.
• This antagonism mechanism involves inhibiting agonist-mediated TCR down-regulation and early signal transduction.
• HCV employs HVR1 variants as a strategy to evade protective CD4+ T cell-mediated immune responses.